A decision analytic tree and a long-term Markov model represented the risk of perinatal and childhood infections under different prevention alternatives, and the long-term health and economic consequences of HepB infection. Outcome measures were the number of perinatal infections and childhood infections from infants born to HepB surface antigen-positive women, quality-adjusted life-years (QALYs), lifetime costs, and incremental cost per QALY gained. The health outcomes and total costs of each strategy were compared incrementally. Costs were evaluated from the health care system perspective and expressed in US dollars at a 2010 price base.
To analyze the cost-effectiveness of the national Perinatal Hepatitis B Prevention Program (PHBPP) over the lifetime of the 2009 US birth cohort and compare the costs and outcomes of the program to a scenario without PHBPP support. PHBPP' s goals are to ensure all infants born to hepatitis B (HepB) surface antigen-positive women receive timely postexposure prophylaxis, complete HepB vaccine series, and obtain serologic testing after series completion.
METHODS:
A decision analytic tree and a long-term Markov model represented the risk of perinatal and childhood infections under different prevention alternatives, and the long-term health and economic consequences of HepB infection. Outcome measures were the number of perinatal infections and childhood infections from infants born to HepB surface antigen-positive women, quality-adjusted life-years (QALYs), lifetime costs, and incremental cost per QALY gained. The health outcomes and total costs of each strategy were compared incrementally. Costs were evaluated from the health care system perspective and expressed in US dollars at a 2010 price base.
RESULTS:
In all analyses, the PHBPP increased QALYs and led to higher reductions in the number of perinatal and childhood infections than no PHBPP, with a cost-effectiveness ratio of $2602 per QALY. In sensitivity analyses, the cost-effectiveness ratio was robust to variations in model inputs, and there were instances where the program was both more effective and cost saving.
CONCLUSIONS: This study indicated that the current PHBPP represents a cost-effective use of resources, and ensuring the program reaches all pregnant women could present additional public health benefits. Each year, an estimated 25 000 infants are born to hepatitis B surface antigen (HBsAg)-positive women in the United States. 1 With no intervention, these infants have a 40% to 90% risk of hepatitis B virus (HBV) infection. 2, 3 Approximately 90% of infected infants develop chronic HBV infection, which carries a 25% risk of premature death from progressive damage to the liver, leading to cirrhosis, or cancer of the liver. 4 Postexposure prophylaxis (PEP), consisting of hepatitis B immune globulin (HBIG) and hepatitis B (HepB) vaccine administered at birth, followed by completion of a 3-dose HepB vaccine series is 85% to 95% effective in preventing perinatal HBV infection. 4 The Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) recommends that all pregnant women receive HBsAg screening to ensure that infants of HBsAg-positive women receive PEP. 4 ACIP recommends that infants of HBsAg-positive women receive HBIG and HepB vaccine within 12 hours of birth, complete the HepB series, and receive serologic testing (HBsAg and antibody to HBsAg) 1 to 2 months after completing the HepB vaccine series to determine outcomes (HepB immunity by vaccination, nonresponse to vaccination, or chronic HBV infection) and future management. ACIP also recommends that the small percentage (5%) of infants who fail to respond to an initial HepB vaccine series and remain uninfected receive an additional HepB vaccine series and repeat postvaccination serologic testing (PVST). Although economic analyses of the burden and prevention impact of HBV transmission have been conducted, 2, [5] [6] [7] [8] [9] [10] no study has focused on the long-term costs and outcomes of PEP through the current national PHBPP. This study analyzes the effects of the PHBPP on health and economic outcomes attributable to perinatal and early childhood infection (postnatal infection, before age 5 years), determined over the lifetime of the 2009 US birth cohort. Costs and outcomes of the current PHBPP ("PHBPP" strategy) are compared incrementally to a strategy represented by the ACIP recommendations without PHBPP support ("No PHBPP" strategy). The study' s main hypotheses were as follows 1 : the number of perinatal and childhood infections will be lower in the PHBPP strategy, 2 the higher qualityadjusted life-years (QALYs) gained with PHBPP will justify the higher program costs, and the program will be costeffective when compared with the No PHBPP strategy.
METHODS

Overview
Economic evaluation provides a framework to allocate resources to effective strategies. Full economic evaluations are evaluations where the costs and consequences of at least 2 strategies are compared and can help with understanding the value for money of each strategy. 11, 12 Where 1 strategy does not dominate (ie, is not both more effective and less costly), costs and effects are combined in the form of incremental cost-effectiveness ratios (ICERs), defined as the difference in costs (C) divided by the difference in mean effectiveness (E), (Cj2Ci)/(Ej2Ei), where j is a more costly strategy than i. The ICER represents the additional cost required to achieve 1 additional unit of outcome. An optimal intervention is one with an ICER that is not more than the decision maker' s intrinsic valuation for an additional unit of the outcome. The costs and outcomes of the strategies analyzed in this study were calculated by using a decision-analytic model. The model was constructed in 2 parts, a decision analytic tree and a long-term Markov model, both following a cohort simulation approach. 13, 14 Decision Analytic Tree
The decision tree estimated the expected number of infants, born to HBsAgpositive women, who were perinatally and postnatally infected and was used in all cost-effectiveness analyses. We defined early diagnosis as diagnosis of infection soon after infection (100% probability of diagnosis for infants who are serologically tested) and late diagnosis as detection of infection at a 1% annual rate, [20] [21] [22] or when the infection becomes symptomatic. We estimated hepatitis-related costs and QALY loss for early and late diagnosis and for perinatal and childhood infection. Table 1 shows that perinatal infections have higher costs and greater QALY losses than childhood infections, because chronic HBV infection is more common after perinatal infection (90% vs 30%). 4 For both types of infections, early diagnosis leads to earlier and more monitoring, and more effective treatment than late diagnosis, resulting in higher costs but lower QALY loss. Appendices A and B in the Supplemental Information provide detailed explanations of the calculation of each parameter in Table 1 and a detailed description of the Markov model, respectively.
Analysis Outcomes
The combined decision tree and Markov models quantified the number of perinatal and early childhood infections from infants born to HBsAg-positive women. The other main outcome measures were QALYs, lifetime costs, and incremental cost per QALY gained. Costs were evaluated from the health care system perspective and expressed in 2010 US dollars. Future costs and QALYs were discounted at a 3% annual rate. 11, 12 For each strategy, expected health outcomes were the number of perinatal and childhood infections and QALYs lost with infection. Expected total costs were the sum of strategy costs and the present value of discounted future health care costs associated with monitoring and treating HBV infection and its complications.
Cost-effectiveness Analysis
ICERs were estimated. 23 The ICER represents the additional cost to achieve 1 less QALY loss due to infection. The preferred strategy is determined by comparing the ICER to what decision makers are willing to pay for an additional QALY. No consensus has been reached on decision makers' willingness to pay in the United States, although a $50 000/QALY benchmark has been used in several studies. 24 Probabilistic sensitivity analysis was conducted to incorporate uncertainty in model parameters. Monte Carlo simulation was used to calculate the combined impact of the model' s various uncertainties. 25 The distributions used are presented in Table 1 . Uncertainty in the model was described using a costeffectiveness acceptability curve (CEAC) 23 to graphically show the probability that 1 strategy is more cost-effective than the other based on decision makers' willingness to pay for an additional QALY. 11, 23 Sensitivity Analyses
One-way sensitivity analyses were conducted to estimate the impact of changing each key parameter individually. A series of multiway sensitivity analyses changed several variables simultaneously to create 6 hypothetical scenarios: (1) pessimistic and optimistic vaccine efficacy scenarios, using lower or upper bounds of the confidence interval (CI) from Lee et al 26 for first dose of vaccine and HBIG and 50% or 10% cut in the remaining variables' efficacy, respectively; (2) no maternal screening cost: the cost of screening all pregnant women in both strategies was excluded; (3) same diagnosis probability: assumed all perinatal and childhood infections were diagnosed at infection (early diagnosis); (4) makers are willing to pay at least $2602 per QALY gained, the PHBPP can be considered cost-effective. Figure 2 presents the CEAC. The probability that the PHBPP is cost-effective increases as health gains are more highly valued; if decision makers are willing to pay ∼$6000 for an additional QALY, the PHBPP is cost-effective. Figure 3 shows the effect of the 1-way sensitivity analyses on the ICERs. The probability of HBV transmission had the highest impact on the ICER. With higher transmission probabilities, the program was more cost-effective, and with lower transmission probabilities, the ICER was higher. Overall, changing each variable had a moderate to small effect, and the ICER never surpassed $6500 per QALY. Table 3 presents the results of the multiway sensitivity analyses. Under a pessimistic vaccine efficacy scenario, the PHBPP was slightly more costly and less effective than in the base-case scenario, with a slightly higher ICER ($3060 per QALY). Under the optimistic vaccine efficacy scenario, the PHBPP had lower costs and higher QALYs gained than in the base-case scenario. Excluding the cost of screening all pregnant women did not have an impact on the ICER. With early diagnosis of all infections, the PHBPP was costsaving (less costly and more effective than vaccination only). This is caused by the higher cost and lower QALY loss related to early diagnosis of perinatal 
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FIGURE 2
Base-case results in the form of a CEAC. The CEAC shows the probability that 1 strategy is preferred to the other, for different maximum willingness to pay for an additional QALY. As decision makers are willing to pay more for an additional QALY, the more costly and effective strategy is preferred. 32 Despite the small number of studies, the estimates are within the range of results from studies not included because they were not randomized controlled trials. 33, 34 The efficacy of HepB vaccine and HBIG when the first dose is delayed and when all vaccine doses are not completed on time was determined by the authors' calculations relying on 2 studies. 17, 18 These areas of uncertainty were considered in the probabilistic and multiway sensitivity analyses.
Another important data limitation relates to the cost of the PHBPP. Program costs were based on aggregate data reported by PHBPP grantees. We excluded outliers and used bootstrap techniques to account for imperfections of the data. However, it is possible that cross-subsidies (eg, office space, utilities, shared equipment, hospital personnel time for communication, and liaising with PHBPP staff) were not captured in the reports. More accurate costs are needed for future analyses.
In addition to the data limitations, more general issues remain. Some benefits of the PHBPP have been underestimated. Recent evidence suggests vaccination confers immunity into early adulthood. [35] [36] [37] This study did not account for infections avoided at later stages in life (eg, during adolescence and adulthood 
